SciELO - Scientific Electronic Library Online

 
vol.5 issue2Prospective assessment of clinical outcomes of transcatheter aortic valve implantation in a cohort of patients based on their risk profileRegional differences in STEMI care in Spain. Data from the ACI-SEC Infarction Code Registry author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


REC: Interventional Cardiology

On-line version ISSN 2604-7276Print version ISSN 2604-7306

Abstract

SORIA JIMENEZ, César E et al. Clinical outcomes of patients undergoing percutaneous coronary intervention treated with colchicine. REC Interv Cardiol ES [online]. 2023, vol.5, n.2, pp.110-117.  Epub Mar 18, 2024. ISSN 2604-7276.  https://dx.doi.org/10.24875/recic.m22000353.

Introduction and objectives:

The role of inflammation in the pathogenesis of coronary artery disease, and that resulting from percutaneous coronary intervention (PCI) is increasingly recognized, yet the effect of colchicine in attenuating peri-PCI inflammation remains unknown. This meta-analysis investigated the efficacy of colchicine in patients undergoing PCI for secondary prevention of coronary artery disease.

Methods:

The Web of Science, PubMed, Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov databases were searched. Data on studies assessing the efficacy profile of colchicine in patients undergoing PCI were pooled using a random-effects model.

Results:

In 13 studies of 7414 patients, no differences were observed between patients treated with colchicine compared to those without for all-cause mortality (OR, 1.1; 95%CI, 0.72-1.56; I2 = 0%), cardiovascular mortality (OR, 0.98; 95%CI, 0.42-2.28; I2 = 14.2%), myocardial infarction (OR, 0.84; 95%CI, 0.65-1.08; I2 = 1.4%) or coronary revascularization (OR, 0.64; 95%CI, 0.28-1.42; I2 = 49.3%). However, patients treated with colchicine had a lower risk of stroke (OR, 0.33; 95%CI, 0.15-0.72; I2 = 0%).

Conclusions:

Adding colchicine to standard medical therapy in patients undergoing PCI did not decrease all-cause mortality, cardiovascular mortality or urgent revascularization. However, it showed a trend towards a lower risk of myocardial infarction and a significantly lower risk of stroke.

Keywords : Coronary artery disease; Percutaneous coronary intervention; Inflammation; Colchicine.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )